
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
A Silver Lining
over 15 years ago
iLogisticaover 15 years ago
Off-Label But On Point?over 15 years ago
Pharm Exec Wins a Neal Award!over 15 years ago
Espacio Riescoover 15 years ago
Restoring Public Trust in Pharmaover 15 years ago
HBA Woman of the Year: Freda Lewis-Hallover 15 years ago
Revisiting Reform




